




The function of the second	P&T Updates Enoxaparin d	ose adju		
Page 1 of 3 Many Number Many Number Distribution of the second of the sec				
All Clinical Areas every 3 years OUTCOME; To reduce the likelihood of patient harm associated with the use of anticoagulation therapy. DURDSE: To implement a defined anticoagulant management program to individualize the care provided to each patient receiving anticoagulant therapy. Proposed edit: automatic adjustment of ANY prophylactic dose of LMWH – including 30 mg BID dosing d. Low Molecular Weight Heparins (enoxaparin): Lovenox (enoxaparin) dosing protocol available for physician use. The hospital approved dosing for renal failure (CrCl < 30 ml/min), dosing in the elderty (age ≥ 70 yrs), and dosing in obese patients (BMI > 50 kg/m2) is as follows: i. Renal failure (trotphylaxis): Doses of 40 mg daily are automatically reduced by pharmacy to 30 mg daily. iii. Renal failure (trotphylaxis): Horeacy may automatically adjust patients with CrCl < 30 ml/min to 1 mg/kg once daily. iii. Renal failure (trotathent dose): Pharmacy may automatically adjust patients with CrCl < 30 ml/min to 1 mg/kg once daily. iii. Renal failure (trotathent dose): Pharmacy may automatically adjust patients with CrCl < 30 ml/min to 1 mg/kg once daily. iii. Obesity (trotphylaxis): Recommended dose of 40 mg BID. iii. Obesity (trotphylaxis): Recommended dose of 40 mg BID. iii. Obesity (treatment): Actual body weight to be used for dosing in patients > 150 kg. Anti-Xa levels will be monitored following 3rd dose to ensure adequate dosing for patients >	Policy Number: MM-05401			
PUEPOSE: To implement a defined anticoagulant management program to individualize the care provided to each patient receiving anticoagulant therapy. Proposed edit: automatic adjustment of ANY prophylactic dose of LMWH – including 30 mg BID dosing 4. Low Molecular Weight Heparins (enoxaparin): Lovenox (enoxaparin) dosing protocol available for physician use. The hospital approved dosing for renal failure (CrCl < 30 m//min), dosing in the elderly (age > 70 yrs), and dosing in obese patients (BM) > 50 kg/m2) is as follows: • Renal failure (prophylaxis): Doses of 40 mg daily are automatically reduced by pharmacy to 30 mg daily. • Renal failure (treatment dose): Pharmacy may automatically adjust patients with CrCL < 30 m//min (or 10 mg/kg once daily). If CrCl < 30 m//min, pharmacy will order an anti-Xa level to determine if once daily dosing with enoxaparin is appropriate. Abnormal lab results will be communicated directly to physican. • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •			·	
	To implement a defined anticoagulant management pro- receiving anticoagulant therapy. Proposed edit: automatic adjustment of ANY prop d. Low Molecular Weight Heparins (enoxaparin): physician use. The hospital approved dosing f elderty (age > 70 yrs), and dosing in obese path i. Renal failure (prophylaxis): Doses of 4 to 30 mg daily. ii. Renal failure (treatment dose): Pharm 30 ml/min to 1 mg/kg once daily. If C level to determine if once daily dosing results will be communicated directly t iii. Obesity (treatment): Actual body weigi Xa levels will be monitore following 3	hylactic dose of LMWH – inclu Lovenox (enoxaparin) dosing pi or renal failure (CrCI < 30 ml/mi ients (BMI > 50 kg/m2) is as foll 0 mg daily are automatically radjust pa cor may automatically adjust pa CI < 20 ml/min, pharmacy will ou with enoxaparin is appropriate. o physician. dose of 40 mg BID. t to be used for dosing in patier	ding 30 mg BID dosin rotocol available for n), dosing in the lows: luced by pharmacy titents with CrCL < rder an anti-Xa Abnormal lab nts >150 kg. Anti-	g








	Movantik vs. Relistor (injection)				
/		Naloxegol (Movantik)	Methylnaltrexone (Relistor)		
	Time to peak concentration	<2 hours with secondary plasma peak 0.4-3 hrs after initial peak	30 minutes		
	Efficacy Onset	Median time to first SBM:	% of patients with SBM within 4 hrs of first dose:		
		KODIAC-04: 25mg - 5.9 hrs 12.5 mg - 20.4 hrs KODIAC-05: 25 mg - 12 hrs 12.5 mg - 19.3 hrs	Study 1: Methylnaltrexone 12 mg daily - 33% (~50% of patients had SBM within 24 hours) Study 3: Methylnaltrexone 0.15 mg/kg - 62% Methylnaltrexone 0.3 mg/kg - 58% Study 4: Methylnaltrexone 0.15 mg/kg - 48%		
	Adverse Effects	Abdominal Pain: 12-21%	Abdominal Pain: 21-29%		
		Diarrhea: 6-9%	Nausea: 9-12%		
		Nausea: 7-8%	Diarrhea: 6%		
		flatulence 3-6%	Flatulence: 13%		
		vomiting 3-5%	Hyperhidrosis: 6%		
		-	Dizziness: 7%		
	Cost (per dose)	\$8.27	\$95.16		
	 Note: Oral formulation of Relistor is also now approved although this is <u>NON-FORMULARY</u> at this time A therapeutic interchange to Movantik will likely be implemented in the coming months (more info on next slide) If you receive orders now call and recommend Movantik as alternative 				


		Movantik (oral)	Relistor (oral)
1	Protein Binding	4.2%	11% to 15.3%
/	Elimination t _{1/2}	6-11 hrs.	15 hrs.
/ 1	T.max.	< 2 hrs.	1.5 hrs.
	Drug Interactions	Contraindicated – strong CYP3A4 Inhibitors (most azole antifungals, many antivirals, clarithromycin, <u>mefazodone</u> , <u>conivaptan</u> , <u>cobicistat</u> , <u>idealisib</u> , <u>imatinib</u>) – Concomitant use is not recommended. Major: CYP3A4 inducers (anti-selzure medications, barbiturates, rifampin, St. John's <u>Wort</u>) – Concomitant use is not recommended Moderate – <u>3A4 inhibitors (diltiazem</u> , erythromycin, verapamil) Increased <u>naloxegol</u> concentrations; avoid concomitant use; if unavoidable, reduce dosage to 12.5 mg ONCE daily.	Major: selected opioid antagonists can increase withdrawal
	Adverse Effects	Diarrhea, N/V, flatulence, arthralgia, headache, abdominal pain, GI perforation, withdrawals	Abdominal pain, flatulence, nausea, GI perforation, withdrawals
	Dosing	25 mg <u>po gam</u> Take at least 1 hour before or 2 hours <u>after</u> the first meal of the day; Avoid grapefruit products	450 mg <u>po gam</u> Take with water 30 minutes prior to first meal of the day
	Dose Adjustments	Renal: <u>CrCl</u> < 60 mL/min: 12.5 mg <u>gam</u> Hepatic, severe: avoid use	Renal: CrCl < 60 mL/min: 150 mg po gam Hepatic, moderate to severe: 150 mg gam
	Time to First Bowel Movement	Avg: 6 hours (@25 mg); 20 hours (@12.5 mg)	Within 4 hours: 50.5% (450 mg); 47.8% (300 mg); 41.3% (150 mg)














Theradoc
Intervention Documention
 DO NOT USE Meditech Cl's to communicate issues (see below)
Logout issue
 May use CITRIX or use internet explorer directly
 CHI is investigating the logout issue and we are hopeful this will be resolved soon
Password expiration – If you have an alternate network ID
Patient TEST,TEST Start 11/03/16 1009 Туре CLAR-DOSE Clarify Drug, Dose, Schedule HL Fcn Cnt Status COMPLETE Сомріете User PHAPNE MR Form? N
Edit Text

Theradoc CI Observations: • IV to PO conversio PO rule. I believe t	Theradoc – Cl documentation ns: I am working with Theradoc on some issues that we have discovered regarding the alert his has detrimentally impacted our IV to PO numbers for the past two months. Continue to not "re-firing" and behaving as expected.	logic for their IV to
capturing this work o <u>Discharge o</u> • 1-N	iliation activities – we are now HEAVILY involved in med-rec activities and we need to mak involved in med-rec activities and we need to mak involved in the second seco	u counsel at discharge tion Education" CI)
Remove All	discharge Search	
☑ 1Hr/NP Discharge counseling/education ☑ Discharge Medication Reconciliation	Clinical Activities >> Search Results 4 results found. J. HH/(MNP Discharge counseling/education J. HH/(MNP Discharge Counseling/education Teaching/Discharge Education J. Discharge Medication Reconciliation Program Enrollment and Discharge Prescription Coordination	
• Ple cla o <u>Med-rec A</u>	<u>clarifications, etc.</u> ase also use the "Admission Medication Reconciliation" for any home med clarifications tha ifying (ED tech follow up calls, etc.) <u>DE Minor & Major</u> addition to the above mentioned CI's also document any ADE preventions using either the r	

